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Immunological correlates of 
mycobacterial growth inhibition 
describe a spectrum of tuberculosis 
infection
Matthew K. O’Shea1,2, Rachel Tanner1, Julius Müller  1, Stephanie A. Harris1, Danny Wright1, 
Lisa Stockdale3, Elena Stylianou1, Iman Satti1, Steven G. Smith3, James Dunbar4, 
Thomas E. Fletcher5, Martin Dedicoat6, Adam F. Cunningham7 & Helen McShane1
A major contribution to the burden of Tuberculosis (TB) comes from latent Mycobacterium tuberculosis 
infections (LTBI) becoming clinically active. TB and LTBI probably exist as a spectrum and currently there 
are no correlates available to identify individuals with LTBI most at risk of developing active disease. We 
set out to identify immune parameters associated with ex vivo mycobacterial growth control among 
individuals with active TB disease or LTBI to define the spectrum of TB infection. We used a whole 
blood mycobacterial growth inhibition assay to generate a functional profile of growth control among 
individuals with TB, LTBI or uninfected controls. We subsequently used a multi-platform approach to 
identify an immune signature associated with this profile. We show, for the first time, that patients 
with active disease had the greatest control of mycobacterial growth, whilst there was a continuum 
of responses among latently infected patients, likely related to the degree of immune activation in 
response to bacillary load. Control correlated with multiple factors including inflammatory monocytes, 
activated and atypical memory B cells, IgG1 responses to TB-specific antigens and serum cytokines/
chemokines. Our findings offer a method to stratify subclinical TB infections and the future potential to 
identify individuals most at risk of progressing to active disease and benefit from chemoprophylaxis.
Interrupting tuberculosis (TB) transmission by prompt diagnosis and treatment of active disease has led to sub-
stantial reductions in TB prevalence and mortality. However, TB still represents a huge challenge to global health 
with an estimated 10.4 million new cases and 1.7 million deaths attributed to TB in 20161. Modeling estimates that 
even if transmission was stopped completely and instantly, reactivation from the 2 billion individuals estimated to 
have latent Mycobacterium tuberculosis (M.tb) infections (LTBI) would cause >100 cases per million population 
in 20502. There is increasing recognition that managing individuals with LTBI is needed3. However, the estimated 
lifetime risk of LTBI progressing to disease is only 12% and there are no tests to identify this population4. A test 
to stratify these high-risk individuals within the latent reservoir would facilitate targeted preventative therapy, 
offering an alternative solution to the economic and logistic challenge of treating the global LTBI population.
Identifying a suitably robust and affordable diagnostic test, capable of distinguishing high and low risk indi-
viduals is problematic. Most research has assessed individual immune parameters or techniques to identify cor-
relates of TB risk and protection5. Given the complexity of TB immunology and pathogenesis a single measure of 
immune function may be insufficient to identify risk of LTBI reactivation and therefore a combination approach 
may be required6.
A new approach is needed to how we view the traditional clinical phenotypic description of TB. The binary 
classification of TB as distinct, homogeneous entities of active disease and LTBI is likely an oversimplification and 
these entities actually show marked biological heterogeneity, corresponding to partially overlapping regions on 
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a spectrum of M.tb infection7,8. This continuous spectrum of responses to M.tb probably reflects the contribu-
tions of innate and acquired immunity to control, resulting in quiescent infection, active/subclinical disease, and 
active/fulminant disease8.
Ex vivo mycobacterial growth inhibition assays (MGIAs) are functional assays that provide a summative 
assessment of a range of immune mechanisms within a biological sample9. In the absence of defined mecha-
nisms, this assay provides an unbiased assessment of mycobacterial control as a measure of anti-mycobacterial 
immunity.
We hypothesised that individuals with different degrees of M.tb infection would show differential 
anti-mycobacterial responses in a MGIA, thus defining a spectrum of infection.
Here, we describe a novel exploratory study using a whole blood MGIA to measure the capacity of individuals 
with active TB disease, LTBI and uninfected healthy volunteers, to control mycobacterial growth ex vivo, before 
and after TB treatment. Characterisation of MGIA control profiles identified associations with several different 
immunological and cellular factors. Based on the delineation of the spectrum of M.tb infection we suggest a pro-
file of active/subclinical disease that may be used in developing predictive models of reactivation.
Results
Demographic and haematological characteristics of study participants. Samples were collected 
from 211 HIV-negative adults, including 21 with active TB disease, 139 with LTBI and 51 uninfected healthy con-
trols (Table 1). Mean age was 27.1 years. Most participants were male (76.3%) and born outside the UK (80.1%). 
Pulmonary TB was the most common diagnosis in active disease (71.4%) and 38.1% were confirmed microbi-
ologically. Each patient with active disease completed 6 months anti-TB treatment. The majority of individuals 
with LTBI (94.2%) completed 3 months of rifampicin and isoniazid preventative therapy.
Ex vivo differential mycobacterial growth is associated with disease state. The functional ability 
of pre-treatment whole blood samples to control mycobacterial growth was evaluated using the MGIA. A total 
of 139/211 results were available using BCG and 171/211 using M.tb in the MGIT assay. Reduced mycobacterial 
growth was seen among individuals with active TB compared to healthy controls (Fig. 1A,B). A wide spectrum of 
growth rates occurred in the LTBI group but significant differences in net growth between active and LTBI groups 
was only seen with the BCG MGIT. When BCG was used in this assay, the level of growth observed was lowest for 
active TB patients, greater growth in samples from latently infected individuals and the greatest growth in healthy 
controls. In contrast, for the M.tb MGIT there was similar control of bacterial growth by samples from active TB 
or latently infected individuals. Net growth was significantly higher with M.tb than BCG for active, LTBI and 
control groups (p = 0.01, p < 0.0001, p < 0.0001, respectively). There was a strong correlation between BCG and 
State of infection P values
Active TB LTBI Controls
P1 P2 P3n = 21 (%) n = 139 (%) n = 51 (%)
Mean age (yrs) [IQR] 33.4 [22.5–44]
23.7 
[19–28.5]
24.1 
[19.4–27] <0.0001 0.0065 0.54
Gender male 16 (76.2) 107 (77.0) 38 (74.5) 0.9966 0.9874 0.9339
Place of birth
UK 9 (42.9) 15 (10.8) 18 (35.3) 0.0008 0.5985 0.0002
Outside UK 12 (57.1) 124 (89.2) 33 (64.7) — — —
Ethnic group
White Caucasian 2 (9.5) 8 (5.8) 18 (35.3) 0.6216 0.0409 0.0001
Sub-Saharan African 4 (19.0) 23 (16.5) 1 (2.0) 0.7580 0.0233 0.0057
Indian subcontinent 13 (61.9) 99 (71.2) 32 (62.7) 0.4452 1.0 0.2906
Other 2 (9.5) 9 (6.5) 0 0.6393 0.0822 0.1159
BCG vaccinated 20 (95.2) 111 (79.9) 31 (60.8) 0.1275 0.0036 0.0135
Culture confirmed TB 8 (38.1) NA NA — — —
System
Pulmonary 15 (71.4) NA NA — — —
Extrapulmonarya 5 (23.8) NA NA — — —
Miliary 1 (4.8) NA NA — — —
Completed treatment 21 (100) 131 (94.2)b NA 0.5982 — —
Post-treatment samples 12 (57.1) 78 (56.1) NA 1.0 — —
Table 1. Characteristics of study participants. Two-tailed P values were calculated by Fisher’s exact test between 
infection states as follows: P1 = Active TB vs LTBI; P2 = Active TB vs Healthy controls; P3 = LTBI vs Healthy 
controls. aExtrapulmonary TB included four lymph node TB and one bone TB. bn = 8 (5.8%) participants with 
LTBI were untreated due to the following reasons: n = 4 were >35 years of age; n = 3 were pregnant; n = 1 
reported drug intolerance shortly after commencing therapy. LTBI = latent TB infection; IQR = interquartile 
range; NA = not applicable.
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M.tb net growth (r = 0.41, p < 0.0001) (Fig. 1C). Thus, greater differential mycobacteria growth occurred in the 
modified BCG MGIT and was dependent upon the infection status of the subject.
Mycobacterial growth increases in the whole blood assay following treatment for TB. The 
MGIT assay was repeated after completion of treatment for active disease and LTBI (n = 62). Significant increases 
in the growth of both BCG and M.tb were observed in each group (Fig. 2A,B). The increase in BCG net growth 
was greatest in blood from the active TB group (mean growth pre- vs post-treatment: active TB, p = 0.006; LTBI, 
p < 0.0001). Similar changes in the growth of M.tb following treatment were also seen (mean growth pre- vs 
post-treatment: active TB, p = 0.031; LTBI, p < 0.0001).
Ex vivo mycobacterial control correlates with haematological parameters. Significant dif-
ferences in pre-treatment haematological parameters were observed (n = 183) (Supplementary Table 1). 
Compared to LTBI or healthy controls, individuals with active disease had significantly more monocytes (both 
p < 0.0001) and fewer lymphocytes (p = 0.017 and p = 0.003, respectively), resulting in a significantly increased 
monocyte-to-lymphocyte (ML) ratio (both p < 0.0001). Haemoglobin concentrations were significantly reduced 
in both active disease and LTBI when compared with uninfected controls (p = 0.038 and p = 0.0003, respectively). 
Following TB treatment, active TB and LTBI patients showed significant reductions in total white cells (p = 0.039 
and p < 0.0001), neutrophils (p = 0.008 and P < 0.0001), monocytes (p = 0.004 and p = 0.041) and platelet count 
(p = 0.026 and p < 0.0001), together with increases in haemoglobin concentration (p = 0.004 and p = 0.014, 
respectively), compared with pre-treatment levels (n = 89). There was a non-significant trend for increased lym-
phocytes in active patients and the ML ratio fell significantly after treatment in this group (p = 0.008).
Given that whole blood samples contain several cellular constituents, which may have anti-mycobacterial 
functions, we examined which factors correlated with the mycobacterial growth rate. For BCG, significant posi-
tive correlations were seen between net growth and lymphocyte counts (rho = 0.19, p = 0.038) and haemoglobin 
concentrations (rho = 0.29, p = 0.002), together with a non-significant negative association between ML ratio and 
mycobacterial growth (rho = −0.16, p = 0.07) (Supplementary Fig. 1A–C). For M.tb, monocyte count and ML 
ratio were significantly negatively correlated (rho = −0.20, p = 0.015; rho = −0.17, p = 0.046, respectively) and 
haemoglobin concentration and mean cell volume were positively correlated (rho = 0.33, p < 0.0001; rho = 0.23, 
Figure 1. Ex vivo differential mycobacterial control is associated with disease state in pre-treatment whole 
blood. Samples were collected from volunteers before starting anti-TB treatment. Whole blood MGIT using 
BCG Pasteur (A) and M.tb H37Rv (B) was performed and data meeting the inclusion criteria (duplicate 
ΔTTP < 6 hours) are shown (BCG: n = 11, n = 93, n = 35; H37Rv: n = 19, n = 101, n = 51; for active TB, LTBI 
and healthy controls, respectively). The association between BCG and H37Rv pre-treatment MGIT results was 
evaluated by Pearson’s correlation (C). Points represent the mean of duplicates; bars represent mean values with 
SD. A one-way multiple comparison ANOVA with Tukey’s post-test correction was performed between the 
groups. *Represents a p-value of <0.05, **a p-value of <0.005, ***a p-value of <0.0005 and ****a p-value of 
<0.0001.
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p = 0.007, respectively) with net growth (Supplementary Fig. 1D–G). In a reversal of the pre-treatment rela-
tionships, significant positive correlations between M.tb net growth and monocyte count (rho = 0.22, p = 0.05) 
and ML ratio (rho = 0.4, p = 0.0005), together with a negative correlation with lymphocyte count (rho = −0.32, 
p = 0.006), were observed after treatment (Supplementary Fig. 1H–J).
Distinct monocyte subsets are associated with differential ex vivo mycobacterial control. 
Monocytes play an important role in the immune response to TB and therefore subsets were characterised in pre- 
(n = 44) and matched post-treatment (n = 22) samples. No differences in the proportion of classical monocytes 
between TB, LTBI and healthy control groups were noted (mean = 90.4%, 85.3%, 88.2%, respectively) (Fig. 3A). 
However, significant increases in the proportion of intermediate monocytes in the M.tb-infected groups com-
pared to healthy controls were seen (mean = 5.9%, 8.7%, 1.9%; active, LTBI, controls, respectively; active vs con-
trols p = 0.012; LTBI vs controls p = 0.0004), together with reductions in non-classical monocytes (mean = 3.6%, 
5.9%, 9.4%; active, LTBI, controls, respectively; active vs controls p < 0.0001; LTBI vs controls p = 0.012) 
(Fig. 3B,C). There was a significant negative correlation between the proportion of intermediate monocytes and 
BCG net growth by MGIA (rho = −0.43, p = 0.02) (Fig. 3D) and positive correlations between non-classical 
monocytes and net growth of both BCG (rho = 0.41, p = 0.03, Fig. 3E) and M.tb (rho = 0.33, p = 0.03, data not 
shown). Following anti-TB treatment there were significant reductions in the proportion of intermediate mono-
cytes (p = 0.037) and increases in non-classical monocytes (p = 0.004) in active TB patients, resulting in profiles 
similar to healthy controls, but no changes among LTBI patients (Fig. 3F,G). There were no changes in classi-
cal monocytes in any group (data not shown). Thus mycobacterial growth inhibition was associated with more 
intermediate and fewer non-classical monocytes and altered subset frequencies typically normalised following 
successful treatment.
Selective B cell subsets increase in M.tb infection and correlate with improved control. There is 
increasing recognition of the role of B cells (BC) in TB and therefore profiles were characterised in pre-treatment 
samples (n = 46). Patients with active TB disease and LTBI had a lower proportion of mature BC than healthy 
controls (median = 16.6%, 12.7%, 19.7%; p = 0.069, p = 0.013, respectively) (Fig. 4A). There was no significant 
difference in the proportions of naïve BC between the groups (Fig. 4B). Classical memory BC (mBC) were sig-
nificantly reduced in the active group compared with healthy controls (Fig. 4C). Proportions of activated and 
atypical mBC were significantly elevated among individuals with active TB and LTBI compared with healthy 
controls, which negatively correlated with mycobacterial net growth in the MGIT assay (rho = −0.48, p = 0.02; 
rho = −0.56, p = 0.007, respectively) (Fig. 4D–G).
IgG1 responses to M.tb-specific antigens correlate with improved ex vivo mycobacterial con-
trol. Serodiagnostics are as yet poorly characterised in the context of M.tb but is a potentially valuable tool. 
We examined the distribution of IgG1 and IgG2 responses to protein and non-protein antigens from M.tb H37Rv 
in pre-treatment serum samples (n = 71). Significant differences in IgG2 responses between TB versus LTBI, 
and TB versus controls, were seen against all antigens (Fig. 5A). A similar pattern was seen with IgG1 responses 
against LAM and culture filtrate antigens (Fig. 5B). The only significant difference in IgG1 responses between 
LTBI and healthy controls was to ESAT-6/CFP-10 (p = 0.024). Anti-ESAT-6/CFP-10 IgG1 responses were signif-
icantly negatively correlated with net growth of both BCG (rho = −0.37, p = 0.013) and M.tb in the MGIT assay 
(rho = −0.36, p = 0.003) (Fig. 5C,D). There was a weaker association between anti-culture filtrate IgG1 and M.tb 
net growth (rho = −0.057, p = 0.05; data not shown).
Figure 2. Enhanced mycobacterial control decreases following TB treatment. Samples were collected from 
volunteers with active TB and LTBI between 1 to 6 months following completion of anti-TB treatment. 
Whole blood MGIT using BCG Pasteur (A) and M.tb H37Rv (B) was performed. Data meeting the inclusion 
criteria (duplicate ΔTTP < 6 hours) are shown. For MGIT data, points represent the mean of duplicates; bars 
represent mean values with SD. A paired t- test was performed to assess net growth before and after treatment. 
*Represents a p-value of <0.05, **a p-value of <0.01 and ****a p-value of <0.0001. Red circles = active TB 
and black = LTBI.
www.nature.com/scientificreports/
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Figure 3. Altered proportions of intermediate and non-classical monocyte subsets are associated with differential 
mycobacterial control. Monocyte subsets were characterized among patients with active TB disease (n = 17), LTBI 
(n = 17) and healthy controls (n = 10) before starting anti-TB treatment. The proportions of classical  
(A), intermediate (B), and non-classical (C) monocytes were calculated from the total monocyte population. A 
negative correlation between intermediate monocytes and net growth (D), and a positive correlation between 
non-classical monocytes and net growth (E) of BCG were seen. The latter was also seen with M.tb H37Rv 
(data not shown). Monocyte subsets were then characterized after completion of treatment among active TB 
(n = 11) and LTBI (n = 14) patients. The proportions of intermediate (F) and non-classical (G) monocytes are 
shown. Points are single values and bars represent the mean with SD. After testing for normality, an ordinary 
one-way ANOVA with Tukey’s correction (A,C,G) or a Kruskal-Wallis test with Dunn’s correction for multiple 
comparisons (B,F) was performed. *Represents a p-value of <0.05, **a p-value of <0.005, ***a p-value of 
<0.0005 and ****a p-value of <0.0001. For correlations Spearman’s rho and associated p-values are shown.
www.nature.com/scientificreports/
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Serum cytokine analysis reveals discrete clusters and strong negative correlations with ex vivo 
mycobacterial growth. Differential levels of cytokines/chemokines may indicate immune activation and 
therefore we measured multiple molecules in pre-treatment serum samples (n = 133). Twenty-three analytes were 
Figure 4. Increases in activated and atypical memory B cells occur in M.tb infection and correlate with improved 
mycobacterial control. B cell subsets were characterised among patients with active TB disease (n = 19), LTBI 
(n = 18) and healthy controls (n = 9) before starting anti-TB treatment. The proportions of mature (A), naïve  
(B), classical (C), activated (D) and atypical (E) B cells are shown. Negative correlations between the proportion 
of activated (F) and atypical (G) B cells and BCG net growth were seen. Points are single values and bars represent 
the median with interquartile range. After testing for normality a Kruskal-Wallis test with Dunn’s correction for 
multiple comparisons was performed. *Represents a p-value of <0.05, **a p-value of <0.005, ***a p-value of 
<0.0005 and ****a p-value of <0.0001. Spearman’s rho and associated p-values are shown.
www.nature.com/scientificreports/
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detected. Clustering analysis identified four homogeneous clusters defining two broad groups of individuals: the 
red and blue clusters comprising active and some LTBI patients, and the grey and the black clusters of LTBI and 
control patients (Fig. 6). Specifically, the red cluster contains 10 of the active TB patients, 14 LTBI patients and 2 
controls and features very high levels of FGF-2, IFN-γ, IL-5, IL-6, IL-7, IL-17A, IP-10, TGF-α, TNFα and VEGF 
(cluster 1) and high levels of PDGF-BB, PDGF-AA and Gro (cluster 3). The blue cluster contains the other half 
of the active patients, 30 LTBI patients and 5 controls, and is characterised by high levels of cluster 3 cytokines/
chemokines and low levels of clusters 1 and 2. The black cluster contains 22/30 control patients as well as 18 LTBI 
patients and cytokine cluster 2 levels are highest here. The grey cluster also features lower cytokine cluster 1 levels 
and contains 21/83 LTBI patients and one control patient. Spearman correlation coefficients showed significant 
negative associations between M.tb net growth and serum concentrations of Gro, TGF-α, PDGF-BB, PDGF-AA, 
IP-10, and MDC (Supplementary Table 2).
Discussion
Identifying individuals with LTBI at risk of developing active disease as candidates for preventative treatment 
will be crucial to control TB, and fundamental to achieving this is to understand the full array of infection. We 
present evidence supporting the concept of a heterogenous spectrum of M.tb infection, potentially an important 
initial step in stratifying reactivation risk in LTBI. Using a functional MGIA we developed a continuous ordinal 
scale to define in vivo M.tb infection status, based on an individual’s ex vivo ability to control mycobacterial 
growth. The simple ordinal readout of anti-mycobacterial immunity reflects the summative combination of mul-
tiple individual cellular and non-cellular constituents. The MGIA assay discriminated between individuals with 
different states of M.tb infection, with control of mycobacterial growth greatest in those with active TB and least 
in healthy controls. We hypothesise that the improved control seen in this model may reflect a general state of 
immune activation, generated in response to high in vivo bacillary loads. This may also account for the wide 
Figure 5. IgG1 responses to RD1 restricted M.tb-specific antigens are negatively correlated with mycobacterial 
net growth. Antigen-specific IgG2 (A) and IgG1 (B) responses in pre-treatment samples from active TB 
(n = 21), LTBI (n = 30) and healthy control individuals (n = 20) were determined by ELISA. Negative 
correlations between IgG1 responses to ESAT-6/CFP-10 and BCG (C) and M.tb H37Rv (D) net growth were 
seen. Antigens used were M.tb H37Rv-derived LAM, cell membrane fraction, culture filtrate and ESAT-6/
CFP-10. Optical densities (ODs) are reported following subtraction of the background and plotted on a Log10 
scale. Points represent the mean of duplicates and bars are the median values with the interquartile range. After 
normality testing a Kruskal-Wallis test with Dunn’s correction for multiple comparisons was performed for each 
antigen. *Represents a p-value of <0.05, **a p-value of <0.01, ***a p-value of <0.005 and ****a p-value of 
<0.0001. Spearman’s rho and associated p-values are shown. Red circles = active TB, grey squares = LTBI and 
blue triangles = healthy controls.
www.nature.com/scientificreports/
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spectrum of mycobacterial growth control seen among participants with LTBI, with many overlapping with the 
active and control groups. We suggest that some individuals with a high bacillary burden but subclinical disease 
demonstrate enhanced immune activation and thus bacillary control similar to the active group, whilst those with 
quiescent infection cluster with the healthy controls. This is supported by human intradermal BCG vaccination 
studies, which have shown induction of immune activation and improved growth control in MGIAs10,11. Such a 
principle is well established in animal models of infection, where prior activation macrophages has been shown 
to enhance control of Salmonella typhimurium12.
The significant increases in mycobacterial net growth observed after treatment, which were of greatest magni-
tude among the active disease patients, are consistent with our hypothesis. Individuals with the highest bacillary 
burden, and the greatest immune activation, demonstrated larger changes in growth control after therapy, sup-
ported by resolution of pre-treatment hematological abnormalities.
The differences in the discriminatory power of the MGIT assay using either BCG or M.tb may be due to myco-
bacterial virulence. While significant differences in growth control occurred between all groups when using BCG, 
the M.tb assay was unable to differentiate between active and LTBI groups. We have hypothesised that differential 
mycobacterial control results from immune activation and suggest that the increased virulence of M.tb H37Rv (as 
demonstrated by greater growth rates) may have overcome such activation in the active TB group, thus reducing 
the ability to distinguish between individuals with active TB or LTBI groups. This observation has important 
implications for further work to assess infection stratification using this MGIA.
The heterogeneous responses in the M.tb assay among individuals with active TB may reflect clinical diversity. 
While this heterogeneity did not appear to be associated with different disease states (e.g extrapulmonary versus 
pulmonary TB), this may be due the relatively small extrapulmonary TB sample size in the current study.
The increased ML ratio, neutrophil and platelet counts, and reduced hemoglobin concentrations seen 
here before treatment among individuals with active disease, and some with LTBI, are consistent with other 
reports13–17. Such profiles may result in altered immune-modulatory and anti-mycobacterial functions, resulting 
in enhanced ex vivo control. Bacillary growth correlated with hemoglobin concentration and iron is known to 
augment bacillary replication in MGIA models18,19. The negative association between ML ratio and mycobacte-
rial growth may reflect the balance between innate and adaptive responses in the assay and could prove a useful 
marker of mycobacterial disease risk14,20. Interestingly, after treatment the correlation between mycobacterial 
growth and ML ratio reversed, resulting in profiles very similar to those reported among healthy individuals, sug-
gesting that treatment alters not only the absolute number of myeloid and lymphoid cells, but also their function21.
We used an exploratory multi-platform approach to further characterise the spectrum of mycobacterial con-
trol profiles defined by the MGIA. We observed increased frequencies of intermediate monocytes and decreases 
in non-classical monocytes among individuals with active disease and LTBI, which changed significantly in the 
active group following anti-TB treatment, findings consistent with other reports22,23. There is biological plausi-
bility for the significant correlations between pre-treatment intermediate (negative) and non-classical (positive) 
monocytes and MGIA bacillary growth. Intermediate monocytes typically account for up to 5% of total mono-
cytes, are pro-inflammatory and produce high levels of TNF-α, IL-1β and IL-624,25. Non-classical (‘patrolling’) 
monocytes represent 5–10% of circulating monocytes and survey the endothelium for signs of inflamma-
tion or damage, which induces transmigration and the production of TNF-α and IL-1β25. The sequestration 
of non-classical monocytes in active disease would account for the reduction in peripheral frequencies, while 
enhanced numbers of inflammatory intermediate monocytes in vivo may result in the improved ex vivo myco-
bacterial control.
Figure 6. Serum cytokine analysis reveals discrete clusters, which delineate the spectrum of M.tb infection 
and strong negative correlations with ex vivo mycobacterial growth. Serum cytokine/chemokine responses in 
pre-treatment samples from active TB (n = 20), LTBI (n = 83) and healthy control individuals (n = 30) were 
investigated by Luminex assay. A heatmap of cytokine/chemokine levels (log, row scaled, pg/ml) is shown. 
Samples were clustered according to Spearman correlation distance and the four most distinct clusters were 
coloured in black, grey, blue and red. For clustering of cytokines/chemokines into three clusters, k-means 
clustering was applied to the rows.
www.nature.com/scientificreports/
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While there is increasing evidence of B cell responses to intracellular pathogens, little is known about B cell 
subsets in TB26,27. We found that individuals with active TB had significant increases in activated and atypical 
mBCs and significantly fewer classical mBC. We observed strong negative correlations between the proportion 
of atypical or activated mBCs and ex vivo mycobacterial growth. Atypical mBCs are hypo-responsive cells which 
are thought to be generated from dysfunctional germinal centers or pre-existing classical mBCs28,29. The resulting 
diminished classical mBC frequencies are in agreement with our observations. Increased proportions of atypical 
mBCs occur in active TB and LTBI, and these cells have impaired capacity for proliferation, immunoglobulin and 
cytokine production, which resolves following treatment30. In TB, expanded atypical mBCs and failure of B cell 
responses could contribute to reactivation of LTBI, akin to the reduced malaria immunity observed following 
repeated Plasmodium falciparum infections, which result in expanded atypical mBC populations31.
The ability to discriminate between active TB and LTBI or controls by IgG1 or IgG2 responses is consistent 
with evidence that antibody titers are related to mycobacterial load and disease severity32,33. One of the difficulties 
with TB serodiagnostics is the large overlap in responses, particularly between uninfected healthy controls and 
LTBI34. Prior environmental mycobacteria exposure and BCG vaccination could account for high IgG back-
ground levels. However, IgG1 responses to the RD1-restricted protein antigens ESAT-6/CFP-10 did discriminate 
between LTBI and healthy controls. The strong negative association of these responses with ex vivo mycobacterial 
growth suggests that this M.tb-specific antigen may reflect bacillary burden and therefore disease status. ESAT-6 
and CFP-10 are mainly secreted during bacterial replication but there is evidence for ongoing bacillary replication 
in LTBI35. Anti-ESAT-6/CFP-10 IgG1 responses may correlate with mycobacterial activity, in contrast to the other 
antigens which are likely to be present irrespective of the replicative state of mycobacteria.
Finally, our analysis of serum cytokines/chemokines supports the hypothesis that the magnitude of ex vivo 
inhibition of bacillary growth is related to the degree of in vivo immune activation36. Hierarchical cluster analysis 
highlighted several correlations between high analyte levels and enhanced mycobacterial control. Among these, 
IP-10 and PDGF- BB are particularly noteworthy. The chemokine IP-10 (CXCL10) is involved in the regulation 
of innate and adaptive immune responses through the recruitment of monocytes and activated T-cells to sites of 
inflammation37. High levels of IP-10 have been reported in active TB disease, possibly as a non-specific indication 
of inflammation and immune activation, thus reflecting disease activity38,39. PDGF-BB, an angiogenic growth fac-
tor, was also negatively associated with ex vivo mycobacterial growth. Recent studies have shown increased serum 
levels of PDGF-BB in patients with pulmonary TB, which was associated with pulmonary fibrosis and reduced 
following treatment40,41. Serum PDGF-BB may reflect the number, size and/or composition of pulmonary TB 
granulomas and therefore the underlying state/degree of infection.
There were some limitations to this study. Peripheral blood samples are unlikely to simulate the complexity 
of the pulmonary granuloma in TB, however they are easily accessible and are frequently used in diagnostics, 
allowing comparison between studies. In addition, while we consider our findings biologically plausible, they are 
correlative observations. We did not have the opportunity to investigate underlying mechanisms, which will be an 
Figure 7. A spectrum of M.tb infection and associated immune profiles. We propose that the delineation of 
the spectrum of M.tb infection identified by the MGIT MGIA, and the underlying immunological profiles 
associated with this spectrum, is biologically plausible and may have value in identifying subclinical active TB 
disease and possibly in determining reactivation risk of LTBI.
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area for future studies. Finally, we acknowledge that this exploratory work was not a biomarker study and suggest 
that further studies in independent cohorts are required to validate the MGIA findings and associated immune 
responses presented here.
Using a novel approach we have described the spectrum of TB using a functional MGIA and further charac-
terised immune profiles associated with mycobacterial control responses (Fig. 7). Our findings may have value in 
identifying subclinical active TB disease and possibly in determining reactivation risk.
Methods
Clinical samples. Studies using samples collected from human volunteers were conducted in accordance 
with the principles of the Declaration of Helsinki, Good Clinical Practice, and local ethical and regulatory 
requirements. All volunteers provided informed consent for study participation. Peripheral blood samples were 
collected from HIV-negative adult volunteers (≥18 years) with either a suspected (based on clinical suspicion and 
radiological/histological evidence) or microbiologically confirmed new diagnosis of pulmonary or extrapulmo-
nary TB disease, or with a new diagnosis of LTBI (a positive IFN-γ release assay (IGRA)), in the absence of any 
other significant co-morbidity. Participants were enrolled at one of three clinical sites in Birmingham, Oxford 
or Catterick, UK, under ethical approval granted by the National Research Ethics Service, Heart of England NHS 
Foundation Trust (2012107RM), Committee South Central - Oxford C (12/SC/0299) and the Ministry of Defence 
Research Ethics Committee (MoDREC 237/PPE/11), respectively. In addition, samples were also collected from 
healthy uninfected volunteers (with no past medical history of TB, exposure to M.tb or evidence of LTBI) from 
these sites and also at the Jenner Institute, Oxford, in accordance with Oxford University policy.
Bacterial strains, culture and titrations. All experimental work using M.tb was performed in an 
approved containment level 3 (CL3) laboratory. Frozen 1 ml aliquots of strain stocks were thawed and grown in 
100 ml Middlebrook 7H9 media with 10% OADC to mid-log phase then divided into 1 ml aliquots and stored at 
−80 °C until required. Mycobacterial stocks were titrated by serially diluting in supplemented 7H9 media and 
culturing in BACTEC MGIT tubes supplemented with PANTA antibiotics and OADC enrichment broth (Becton 
Dickinson, UK), as previously described42. In addition, the number of colony forming units (cfu) for each dilution 
was determined by solid culture on 7H10 agar plates. A standard curve of time-to-positivity (TTP) against cfu 
was derived and linear regression analysis generated an equation to convert experimental TTP to cfu.
Ex vivo whole blood MGIA. This assay was performed as previously described19. Duplicate tubes contain-
ing 300 μl of whole blood were incubated with 300 μl of RPMI (containing 10% pooled human serum, 2mM 
L-glutamine and 25 mM HEPES; Sigma, UK) inoculated with ~150 cfu BCG or M.tb on a 360° rotator at 37 °C 
for 96 hours (volume of the mycobacterial stock was calculated to give a TTP of 6.5 days, previously determined 
to give optimal differential responses). Cells were then lysed with sterile water, the mycobacteria resuspended in 
7H9 media and transferred to a BACTEC MGIT tube supplemented with PANTA antibiotics and OADC enrich-
ment broth (Becton Dickinson, UK). Tubes were placed in the BACTEC 960 machine and incubated at 37 °C until 
the detection of positivity by fluorescence (TTP). In addition, on day 0, duplicate viability control tubes were set 
up by directly inoculating supplemented BACTEC MGIT tubes with the same volume of mycobacteria as the 
samples. The mean TTP for duplicates was converted to a cfu count (as described above) and net growth ratio was 
calculated as Log10(sample cfu/control cfu). A smaller net growth value indicates less bacillary replication and 
therefore represents greater mycobacterial control. Samples failing to meet pre-defined reproducibility criteria of 
ΔTTP < 6 hours between duplicates, as determined by initial experiments, were excluded.
Peripheral blood mononuclear cell isolation, cryopreservation and thawing. Peripheral blood 
mononuclear cells (PBMC) were separated from fresh heparinized whole blood obtained from study participants 
by density gradient centrifugation. Briefly, 15–30 ml of whole blood was carefully layered onto the membrane a 
Leucosep tube (Greiner Bio-One) pre-loaded with LymphoPrep™ (StemCell Technologies, France) and centri-
fuged. PBMC were collected from the interface and washed twice with pre-warmed R0 media (RPMI 1640, 2mM 
L-glutamine, 100U/ml penicillin and streptomycin and 1% sodium pyruvate; Sigma Aldrich, UK), then resus-
pended in R10 media (R0 media with 10% fetal calf serum (FCS); Sigma Aldrich) and counted using a CASY® 
counter (Roche, Switzerland). For cryopreservation, cells were centrifuged and resuspended in ice-cold FCS to 
which an equal volume of 20% DMSO in FCS was added to give a concentration of 5–10 × 106 cells/ml, aliquoted 
into cryovials and placed in a CoolCell® cell freezing container which was stored at −80 °C until transfer to 
liquid nitrogen after 1–2 days. Cryopreserved PBMC were rapidly thawed in a 37 °C waterbath, transferred to a 
tube containing pre-warmed R10, centrifuged and resuspended in R10 containing 2 μl/ml of benzonase (Merck 
Chemicals) and rested at 37 °C, 5% CO2, for a minimum of 2 hours before counting and use in subsequent assays.
Immunophenotyping monocytes and B cells. Thawed PBMC were counted and diluted to a final 
concentration of 5 × 106/ml in R10 media. After washing, cells (1 × 106) were stained with Aqua viability dye 
(Invitrogen, USA) before staining with fluorochrome-conjugated antibodies to surface markers. For mono-
cyte immunophenotyping, the surface panel included anti-CD3 AF700 (eBioscience), anti-CD19 Pacific Blue 
(Life Technologies), anti-CD56 Pacific Blue, anti-HLA-DR APC-Cy7, anti-CD14 PE and anti-CD16 PE-Cy7 
(BioLegend). The B cell (BC) surface panel contained anti-CD10 APC and anti-CD19 PECy7 (Becton Dickinson), 
anti-CD21 Pacific Blue (eBioscience) and anti-CD27 Qdot605 (Invitrogen). Cells were stained in batches with 
either the B cell or monocyte panel, washed with FACS buffer (BD Pharmingen) and fixed with 1% paraformal-
dehyde (Sigma, UK). Fluorescence-minus-one (FMO) controls were included in each batch. Compensation was 
performed using CompBeads (BD Biosciences) stained with each fluorophore and compensation matrices were 
calculated with FACSdiva. Stained cells were acquired using an LSRII flow cytometer (BD Biosciences) within 24 
hours and analyzed using FlowJo v8.3 (Tree Star Inc., USA). Gating strategies and an example of raw flow cytometry 
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data are shown in Supplementary Figs 2 and 3. Monocyte subsets were defined as CD14++CD16− (classical), 
CD14++CD16+ (intermediate), or CD14+CD16+ (non-classical), as previously described43. B cell subsets were 
defined as CD19+CD10− (mature B cells), CD27+CD21− (activated memory B cells, mBC), CD27+CD21+ 
(classical mBC), CD27−CD21+ (naïve mBC) and CD27−CD21− (atypical mBC), as previously described44.
Anti-M.tb IgG isotype enzyme-linked immunosorbent assays. Microtiter plates were coated over-
night at room temperature with the following antigens (at final concentrations) prepared from M.tb H37Rv (BEI 
Resources): cell membrane fraction (2 μg/ml), culture filtrate (2 μg/ml), LAM (2 μg/ml) and a 1:1 mix of ESAT-6/CFP-
10 (10 μg/ml each). Each plate was prepared in duplicate to test IgG1 and IgG2 responses, and also included native 
human IgG1 and IgG2 (2 μg/ml; AbD Serotec, UK) as positive controls and PBS as a negative control. After washing 
with PBS containing 0.05%/Tween 20 (PBS/T) and blocking with casein, serum samples were tested in duplicate at 
1:100 (diluted in casein) for all antigens except for ESAT-6/CFP-10 (1:10 dilution). Casein was used for control wells. 
After incubation at room temperature, biotinylated secondary antibody (anti-IgG1 or anti-IgG2; Life Technologies) at 
1:1000 dilution was added, followed by washing and the addition of Extravidin-ALP (1:5000; Sigma Aldrich). pNPP 
substrate (Sigma Aldrich) was added and plates were read at 405 nm every 10 minutes using an ELx800 Microplate 
Reader with Gen5 software until the IgG1 and IgG2 isotype controls reached an optical density (OD) of 0.6 and 1.2, 
respectively (previously determined from the gradient of a standard curve of native human IgG1 or IgG2 ranging 
from 0.1 to 100 μg/ml to avoid saturation). The mean OD of negative controls was subtracted from the mean OD of 
samples and readings with an OD > negative control plus 3 standard deviations (SD) were considered positive.
Multiplex serum cytokine and chemokine analysis. The Milliplex® Map human cytokine/chemok-
ine system (Merck Millipore), based on a luminex bead array platform, was used to measure the concentra-
tions of 41 analytes. Levels of interleukin (IL)-1α, IL-1β, IL-1ra, IL-2, IL-3, IL-4, IL-5, IL-6, IL-7, IL-8, IL-9, 
IL-10, IL-12 (p40), IL-12 (p70), IL-13, IL-15, IL-17A, inducible protein (IP)-10, fibroblast growth factor (FGF)-
2, eotaxin, fractalkine, granulocyte colony stimulating factor (G-CSF), granulocyte macrophage colony stim-
ulating factor (GM-CSF), macrophage inflammatory protein (MIP)-1α, MIP-1β, Flt-3 ligand, platelet derived 
growth factor (PDGF)-AA, PDGF-BB, tumour growth factor (TGF)-α, tumour necrosis factor (TNF)-α, TNF-β, 
vascular endothelial growth factor (VEGF), monocyte chemoattractant protein (MCP)-1, MCP-3, interferon 
(IFN)-α2, IFN-γ, macrophage-dervied chemokine (MDC), epidermal growth factor (EGF), soluble CD40 ligand 
(sCD40L), GRO and regulated on activation, normal T cell expressed and secreted (RANTES) were measured 
in unstimulated serum samples, according to the manufacturer’s instructions. Plates were read using the Biorad 
Luminex®100™ system and analyzed with integrated Bioplex Manager Software v6.1 (Biorad Corp., USA). Values 
above or below the concentration range for each analyte (3.2 to 10,000 pg/ml) were derived from analyte-specific 
standard curves by extrapolation. Below the lowest extrapolated value a concentration of zero was recorded.
Statistical analysis. Analyses used Prism (v6.0) and SPSS (v22). The D’Agnostino-Pearson omnibus test 
was used to assess normality of data. Mean values of parametric data were compared between groups using 
paired t-tests, unpaired t-tests, repeated measures and one-way ANOVAs, with Dunnett’s post-test correction for 
multiple comparisons. Median values of non-parametric data were compared between groups using Wilcoxon 
matched-pairs signed rank tests, Mann-Whitney tests, and Kruskal-Wallis tests, with Dunn’s post-test correction. 
For correlation analyses, Pearson’s or Spearman’s tests were performed after testing for normality. Reported P 
values are two-sided and a value of less than 0.05 was considered significant. For hierarchical clustering, luminex 
data were log transformed, mean centered and scaled. One minus Spearman correlation coefficients were then 
used as dissimilarity metrics to cluster samples, and average linkage as the agglomeration rule was used as imple-
mented in the hclust command in R. Clusters were then coloured according to branch height and the number of 
most informative clusters was estimated to be four by the method described in as implemented in the package 
NbClust45,46. The final Heatmap was assembled using the ComplexHeatmap package in R47.
Data Availability
All data generated or analysed during this study are included in this published article (and its Supplementary 
Information files).
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